Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is 14.46% higher on its value in year-to-date trading and has touched a low of $5.84 and a high of $17.02 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHAT stock was last observed hovering at around $11.02 in the last trading session, with the day’s loss setting it -0.57%.
Currently trading at $10.45, the stock is 11.74% and 26.15% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing -5.17% at the moment leaves the stock -0.48% off its SMA200. PHAT registered 66.40% gain for a year compared to 6-month loss of -1.69%. The firm has a 50-day simple moving average (SMA 50) of $540.65 and a 200-day simple moving average (SMA200) of -$2.32.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.42% gain in the last 1 month and extending the period to 3 months gives it a 16.37%, and is 26.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.05% over the week and 9.48% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $611.12M and $0.68M in sales. Profit margin for the company is -29558.80%. Distance from 52-week low is 78.94% and -38.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.18%).
Phathom Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$1.18 with sales reaching $2.41M over the same period.The EPS is expected to shrink by -17.60% this year, but quarterly earnings will post 6,285.60% year-over-year.
Phathom Pharmaceuticals Inc (PHAT) Top Institutional Holders
171 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 97.42% of the company’s shares. The shares outstanding are 57.97M, and float is at 26.03M with Short Float at 33.31%. Institutions hold 87.20% of the Float.
The top institutional shareholder in the company is Frazier Life Sciences Management, L.P. with over 10.11 million shares valued at $144.76 million. The investor’s holdings represent 17.80% of the PHAT Shares outstanding. As of Sep 29, 2023, the second largest holder is Medicxi Ventures Management (Jersey) Ltd with 3.76 million shares valued at $39.0 million to account for 6.62% of the shares outstanding. The other top investors are Carlyle Group Inc. which holds 3.5 million shares representing 6.16% and valued at over $50.07 million, while Invesco Ltd. holds 5.87% of the shares totaling 3.33 million with a market value of $47.72 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider sale by TAKEDA PHARMACEUTICAL CO LTD,the company’s10% Owner. SEC filings show that TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of the company’s common stock on Jan 24 ’24 at a price of $8.10 per share for a total of $30.0 million. Following the sale, the insider now owns 3.76 million shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 19 ’24 that Henderson Molly (CFO and CBO) sold a total of 6,307 shares of the company’s common stock. The trade occurred on Jan 19 ’24 and was made at $7.75 per share for $48900.0. Following the transaction, the insider now directly holds 98698.0 shares of the PHAT stock.
Still, SEC filings show that on Nov 20 ’23, Henderson Molly (CFO and CBO) disposed off 2,127 shares at an average price of $7.24 for $15403.0. The insider now directly holds 103,061 shares of Phathom Pharmaceuticals Inc (PHAT).
